ArticleAdvances in therapy2019
Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study.
Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06121999 (13-Week Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
13-Week Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatosis (MASH) in Adults: A Randomized Control Trial
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Discrete Choice Experiments and Conjoint Analyses in Health Screening Programs for Type 2 Diabetes and Liver Disease: A Scoping Review.Canadian liver journal · 2025Pooled it
- Patients' Experience of Stigma as the Hidden Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Descriptive Qualitative Study with Thematic Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study.BMJ open gastroenterology · 2025Article
- Information Deficits, Information Needs, and Preferences Regarding eHealth in a Dutch Population With Metabolic Dysfunction-Associated Steatotic Liver Disease: Cross-Sectional Survey Study.JMIR formative research · 2025Article
- Illness perception, coping and psychological distress among patients with metabolic dysfunction-associated fatty liver disease (MAFLD) in China.BMC public health · 2025Article
- Review
- Experiences and Support Needs of Caregivers of Patients with Higher-Risk Myelodysplastic Syndrome via Online Bulletin Board in the USA, Canada and UK.Oncology and therapy · 2024Article
- Patient perspectives on current and potential therapies and clinical trial approaches for cocaine use disorder.Frontiers in psychiatry · 2024Article
- Understanding the patient and supporter journey in cocaine use disorder.Frontiers in psychiatry · 2024Article
- Patient Preferences for Treatment in Relapsed/Refractory Acute Leukemia in the United Kingdom: A Discrete Choice Experiment.Patient preference and adherence · 2024Article
- Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy.Pragmatic and observational research · 2024Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.Journal of clinical medicine · 2023Review
- Barriers and enabling factors in weight management of patients with nonalcoholic fatty liver disease: A qualitative study using the COM-B model of behaviour.Health expectations : an international journal of public participation in health care and health policy · 2023Article
- Factors influencing adherence to lifestyle prescriptions among patients with nonalcoholic fatty liver disease: A qualitative study using the health action process approach framework.Frontiers in public health · 2023Article
- The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.JHEP reports : innovation in hepatology · 2022Article
- Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?World journal of hepatology · 2022Review
- Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review.JHEP reports : innovation in hepatology · 2021Article
- Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway.Journal of patient-reported outcomes · 2021Article
- Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study.BMJ open gastroenterology · 2021Article
- Patient Needs, Perceptions, and Attitudinal Drivers Associated with Obesity: A Qualitative Online Bulletin Board Study.Advances in therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionThe aim of this work was to understand how patients with non-alcoholic steatohepatitis (NASH) perceive their disease, unmet needs, and expectations regarding future treatment through online bulletin board (OBB) qualitative research.
methodsOBB is an asynchronous online qualitative market research tool that provides an open forum for interactive discussion among participants. Patients with NASH were recruited via physician referral and completed a screener questionnaire to ensure their eligibility and willingness to participate. A trained moderator managed the discussion that allowed open answers and responses to other participants' posts. Patient responses were analyzed using a combination of different qualitative analytical tools.
resultsThe OBB ran for 4 days and included 16 patients (n = 8, UK; n = 8, US) with NASH (fibrosis stages F1-F3) and comorbidities including diabetes/prediabetes (n = 9) and obesity (n = 12). The key insights were (1) patients with NASH have a poor understanding of the disease, its progression, and management-they feel a lack of adequate educational support from their physicians; (2) diagnosis of NASH is incidental in most cases, mainly because patients fail to spontaneously associate their signs or symptoms with their liver condition; (3) comorbidities (obesity and diabetes) are more concerning to patients than NASH; and (4) patients perceive that NASH impacts their social life and work performance in more advanced stages.
conclusionsThis OBB provided valuable patient insights into NASH disease perception and management and revealed unmet need areas. In light of no approved therapies, these patient insights can inform early drug development strategies and stakeholder discussions on NASH.
fundingNovartis Pharma AG, Basel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.